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a b s t r a c t
Purpose: The POP-ART RT study aims to determine to what extent and how intrafractional real-time res-
piratory motion management (RRMM), and plan adaptation for interfractional anatomical changes (ART)
are used in clinical practice and to understand barriers to implementation. Here we report on part II: ART
using more than one plan per target per treatment course.
Materials and methods: A questionnaire on the current practice of ART, wishes for expansion or imple-
mentation, and barriers to implementation was distributed worldwide. Four types of ART were discrim-
inated: daily online replanning, online plan library, protocolled offline replanning (all three based on a
protocol), and ad-hoc offline replanning.
Results: The questionnaire was completed by 177 centres from 40 countries. ART was used by 61% of
respondents (31% with protocol) for a median (range) of 3 (1–8) tumour sites. CBCT/MVCT was the main
imaging modality except for online daily replanning (11 users) where 10 users used MR. Two thirds of
respondents wished to implement ART for a new tumour site; 40% of these had plans to do it in the next
2 years. Human/material resources and technical limitations were the main barriers to further use and
implementation.
Conclusions: ART was used for a broad range of tumour sites, mainly with ad-hoc offline replanning and
for a median of 3 tumour sites. There was a large interest in implementing ART for more tumour sites,
mainly limited by human/material resources and technical limitations. Daily online replanning was pri-
marily performed on MR-linacs.
 2020 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 153 (2020) 88–96 This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Radiation therapy (RT) is usually delivered over several frac-
tions using a treatment plan optimised on a CT-scan obtained days
or even weeks prior to treatment start. However, several tumour
sites present important anatomical variations during the course
of treatment, which can happen on various time-scales from
seconds to weeks [1]. Population-based margins [2], used to
increase the probability of target coverage, may result in large irra-
diated volumes, potentially leading to prohibitive toxicity risks,
and/or hampering tumour dose escalation. Image-guided radio-
therapy (IGRT) has enabled considerable margin reduction by
improving set-up accuracy [3]. Yet, anatomical changes caused
by weight loss, tumour regression, variations in organ filling, or
other target and organ shape changes cannot be solely addressed
with translational and/or rotational set-up corrections [1].
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Adaptive RT (ART), using more than one treatment plan per target
per treatment course aims at counteracting the negative dosimet-
ric impact of these changes, potentially improving target coverage
and/or organ at risk (OAR) sparing with respect to the original plan
[4]. Depending on the approach and tumour site, the need for a
change in treatment plan is derived from offline or in-room (on-
line) imaging [5,6].
Offline adaption is suitable for systematic or slow progressive
changes (e.g. tumour regression, weight loss) [6]. The decision to
adapt can be taken ad-hoc by the treatment team based on an
observed deviation in anatomy (on imaging or visible physical
alterations), or following a protocol with predefined action levels
and/or surveillance scans [4,7–10]. Online adaption using a plan
library is well suited for tumours with predictable, potentially
large and frequent interfractional anatomical variations while
intrafraction changes remain comparatively small. Examples are
bladder [11,12], cervix [13,14] or rectum [15–17] where different
bladder or rectal fillings can be anticipated and a library of plans
covering several scenarios are made available for treatment. Online
daily replanning can address any type of anatomical changes but is
the most resource-demanding approach and as such, its clinical
implementation has only been demonstrated in few treatment
sites and institutions so far [18–22].
Challenges to the clinical use of ART include the added work-
load [4], longer daily treatment time [5], limited image quality
[23], RTT training [24,25], uncertainty in dose accumulation [26],
and software or workflow implementation [5,27].
Despite these challenges, there is growing evidence that ART
can provide a favourable dosimetric and clinical outcome com-
pared to standard IGRT potentially allowing for safe margin reduc-
tion [8,11,20,23,28]. The patterns of practice for adaptive and real-
time radiation therapy (POP-ART RT) survey was developed to
determine to which extent and how real-time RT and ART are used
in clinical practice for external beam photon RT, and to understand
the barriers to implementation or further use to help promote the
safe and effective use of these methods as a standard of care. The
present paper addresses the second part: ART for interfractional
anatomical changes1 using multiple plans per tumour and treat-
ment course. Intrafractional anatomical changes caused by respira-
tion can be mitigated by real-time respiratory motion management
(RRMM) [29], which is the topic of an accompanying paper [30].
Materials and methods
The web-based questionnaire, developed during the 2nd ESTRO
physics workshop and further described in [30] and the supple-
mentary materials, contained 16 questions covering ART. Data
were collected between February and July 2019. The questionnaire
was mainly addressed to clinical physicists but surveyed institu-
tional practice. Centres that did not perform ART (yet) were
encouraged to respond nonetheless and fill the wish-list and barri-
ers questions.
Similar subgroup analysis to that of part I [30] was performed
based on type of institutions (academic, public, private), socio-
economic status [31,32] (low, middle, high-income) and patient
volume (<1000, 1000–2000, >2000 patients per year).
Patterns of practice for ART
Four ART strategies were considered (question (Q) 1, page (P)
18):
1. offline ad-hoc (e.g. occasional detection of tumour shrinkage,
weight loss)
2. offline protocol using either:
a. pre-defined action levels based on in-room imaging (e.g.
geometric deviations above a certain threshold on CBCT,
observed by RTT) with referral of the decision to adapt to
the clinician/physicist for subsequent fractions
b. using scheduled surveillance scans (e.g. at given fraction
numbers) and the decision to adapt is taken either by the
clinician or based on objective measures similar to a.
3. online using a plan library
4. online using daily replanning.
Respondents using offline ART (1 or 2 above), were asked which
percentage of the patients were getting more than one plan per
tumour and course (Q2, P19, not applicable for online approaches).
Respondents using ART (‘‘users” hereafter) were asked for each
tumour site:
– what type of imaging was used to guide ART and the reasons for
adaption (Q3/4 P19/20)
– what type of software was used for the ART procedure (Q5/6,
P20/21)
– what additional quality assurance (QA) was performed on the
adapted plan (Q7, P22)
– how was adaption documented (Q8, P23).
Wish-lists and barriers
Similar to part I [30], users were asked if they wished to
increase their use of ART or modify their technique in the next
two years and for which tumour site in priority (P24) and to rank
barriers in order of importance (barriers not considered relevant
were not ranked) (P25).
All respondents (users and non-users) were asked if they
wished to implement ART for any new tumour site and which
one(s) in priority (P27). Barriers to implementation were also
ranked (P28).
Results
The ART questions were completed by 177 institutions from 40
countries (Table A.1). Sixty-one percent (108/177) of respondents
were users of ART for a median (range) of 3 (1–8) tumour sites
(Fig. A.1). However only 31% were using online or offline protocols
for at least one tumour site (maximum 7) (Table 1, Fig. A.1). The
largest group treated with a protocol was bladder (16% of respon-
dents), dominated by the plan library strategy (15%). Offline ad-hoc
adaption was performed by half the respondents, with head and
neck and lung cancer being the largest groups across all subgroups
of respondents (Table 1, Table A.2).
In addition to the tumour sites explicitly mentioned in the
questionnaire and indicated in Table 1, four respondents used
ART for sarcoma (offline ad-hoc), two for anal canal (offline, one
protocolled and one ad-hoc), two for oesophagus (one daily replan-
ning on MR-linac, one offline protocolled), two for lymphoma (one
ad-hoc, one not specified), one for oligometastatic lymph nodes
(plan library), one for cranial SRS (offline ad-hoc) and one respon-
dent for liver, pancreas and abdomino-pelvic metastases (online
daily replanning on MR-linac).
The use of online or offline protocols was dominated by aca-
demic centres where 48% of the respondents used such methods,
while this was reduced to 24% and 28% for private and public cen-
tres respectively (Table A.2). Private centres also differed in the
most common group for protocolled ART – cervix and head and
neck – instead of bladder. Only 6% of respondents applied online
replanning for at least one treatment site (Table 1), with the1 Adaption to biological changes are considered beyond the scope of this study.
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highest percentage observed for academic centres, and no applica-
tion in middle-income countries (Fig. A.2).
For selected tumour sites, the fractions of users applying speci-
fic ART strategies are shown in Fig. 1 with colour-coding for the
percentages of patients receiving more than one plan for the offline
approaches (not applicable for online ART). For lung and head and
neck cancer, 50% or more of the patients were replanned by less
than 20% of the users of ad-hoc adaption. This increased to 35%
by the users of offline protocols.
Most adaptions were aimed at improving both target coverage
and OAR sparing (Fig. 2, Fig. A.3). The main imaging modality for
ART was CBCT/MVCT (>80%), while EPID was used by up to 20%
of the users for offline adaption (Fig. 3a). A substantial proportion
of users reported using CT or MR in combination with other imag-
ing techniques. The use of MR was highest in academic centres,
while the use of CT was highest in middle-income countries
(Fig. A.4a). In addition, three users reported ‘‘poor mask fitting”
as a trigger for ad-hoc adaption in head and neck cancer. Of the ele-
ven users of online daily replanning, one used CT (cervix) while all
others used MR.
Pre-treatment phantom measurements and secondary dose cal-
culations were the most common forms of QA (Fig. 3b). Four users
reported doing no QA on the adapted plan for at least one adaptive
site. For users from middle-income countries, QA was mostly per-
formed with pre-treatment phantom measurements and no user
used log files (Fig. A.4b).
Although 92% of users used commercial software for the adap-
tion procedure, 19% used in-house software alone or in combina-
tion with commercial software. None used open-source software.
The lack of functionalities in commercial software was the main
reason for using in-house software. Half of the users using only
in-house software for head and neck and lung adaption reported
the cost as the reason not to use commercial software.
Plan adaption was documented in the record-and-verify system
for a majority of users. Four used only spreadsheet to record adap-
tion while four used spreadsheet and record-and-verify. Two users
did not document adaption while one used different methods:
record-and-verify on the MR-linac, spreadsheet or no reporting
for offline or plan library adaption.
Nineteen and 13% of respondents wished to increase their use of
ART or change their technique for head and neck and lung cancer
respectively (representing over 35% of the users for both). In addi-
tion, 14 and 12% of respondents were not applying ART but wished
to implement it in priority for head and neck and lung cancer
respectively (Fig. 4a). Overall, two thirds of all 177 respondents
wished to implement ART for a least one new tumour site; 40%
of these had plans to do it in the next 2 years (Fig. 4b). In addition
to the selected tumour sites, priority for implementing ART was
given to liver (five respondents), pancreas (seven respondents)
and oesophagus (two respondents) while 12 did not specify a
tumour site.
Fifty-seven users ranked the barriers to expand/modify their
ART technique for an existing tumour site. The main barrier was
human resources, ranked first or second by 36 users and considered
‘‘not relevant” by only three users. Equipment/financial resources
and Technical limitations were also considered highly important
by a majority of users while Reimbursement was considered ‘‘not
relevant” by 20 users and of lowest importance by 17 (Fig. 5).
One-hundred-and-five respondents (users and non-users)
ranked the barriers to implementing ART for new tumour sites.
Human resources remained the main barrier with Equipment/finan-
cial resources, Clinical relevance/interest and Technical limitations
were also highly ranked (majority of ranks 1–3). Reimbursement
remained lowly ranked.
Barriers entered as other and comments on the barriers
included the ‘‘lack of interest from clinicians” or ‘‘the department”
(three respondents), ‘‘approval from the authorities” (one respon-
dent) or ‘‘insurance companies” (one respondent), ‘‘lack of clear
reimbursement policy” (one respondent), ‘‘small patient volume”
(one respondent), and ‘‘lack of proactive adaptive protocol” (one
respondent).
The ranking of barriers did not differ substantially from the
overall ranking when analysed by type of institution or socio-
economic status although the number of responses was occasion-
ally very small (Fig. A.5).
The RRMM questions were completed by 200 institutions and
we encourage the reader to see the accompanying paper for details
[30]. All 177 respondents for ART had also completed the RRMM
questions. Out of these 177 respondents, 20% were only RRMM
users, 13% only ART users and 48% were both ART and RRMM users
while 19% were non-users for any treatment site or technique.
Lung was a common treatment site for both parts where 29% of
the respondents were only RRMM users, 19% only ART users and
17% used both RRMM and ART. There was a high interest to
increase the use of/implement both ART and RRMM for lung.
Discussion
This study reports on the use of ART in 177 RT centres from 40
countries and is, to our knowledge, the first worldwide survey on
the patterns of practice for ART. Sixty-one percent of the respon-
dents used ART for a median of 3 tumour sites (Fig. A.1). While off-
line ad-hoc ART was the dominant strategy, more advanced forms
of ART using online or offline protocols remained relatively rare
(Table 1, Fig. A.1).
Head and neck and lung were the most common sites treated
with ART. RRMM was also commonly used for lung cancer [30]
however, mostly for SBRT. For small mobile tumours treated with
SRBT, the margin reduction -and hence lower lung dose- enabled
by RRMM may be clinically beneficial [33]. ART is more commonly
used for locally advanced lung cancer where atelectasis is one of
the main reasons for adaption [7]. Although both ART and RRMM
Table 1
Percentages of respondents (N = 177) that apply certain types of ART for specific tumour sites or overall.
Type of adaption Online plan library Online daily replanning Offline protocol Online or offline protocols Offline
ad-hoc
Any ART
Bladder 15% 0 1% 16% 11% 27%
Cervix 6% 2% 5% 13% 19% 32%
Rectum 1% 2% 2% 5% 13% 18%
Prostate1 <1% 3% 6% 10% 18% 28%
Head and Neck 0 0 10% 10% 45% 55%
Lung 0 0 8% 8% 28% 36%
Breast1 0 0 <1% <1% 5% 6%
Any site 17% 6% 15% 31% 50% 61%
1 Unspecified type of adaption for one user each.
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can be used for the same patients [33], respondents using both
RRMM and ART for lung cancer may use it on different patients.
Although not technically demanding, the use of offline protocols
was limited, but most prevalent in head and neck and lung cancer
(10% and 8% of respondents respectively) (Table 1). Offline proto-
cols resulted in proportionally more replanning than the ad-hoc
approach (Fig. 1) indicating that ad-hoc adaption may not suffice
to identify all the cases that would benefit from replanning. Con-
versely, it may indicate that certain protocols resulted in over-
use of replanning. Certain offline ART protocols use action levels
based on the correlation between observable geometric changes
in images and the dosimetric benefit of adaption [7,10]. Favourable
clinical outcomes have been reported with these approaches
[8,10,23]. However, highly sensitive action levels may result in
frequent adaption with little clinical gain at the cost of a high stress
on human resources. Note also that some users, only rarely adapt-
ing for exceptionally large changes, may have answered they per-
formed ad-hoc adaption for <25% of the patients while others
considered this to be anecdotal and indicated not adapting for
these sites. The rate of ad-hoc adaption for <25% of the patients
must then be interpreted with caution.
Regarding online protocols, 17% of respondents used a plan
library approach while only 6% applied daily replanning. It is unli-
kely that in these centres all patients within one treatment site
were treated with online adaption, but this was not covered in
the questionnaire.
The imaging modality used for ART was mainly CBCT/MVCT for
online plan library and offline approaches (Fig. 3a) but up to 20% of
Fig. 1. For the various tumour sites, fractions (bar heights) of users applying the defined four types of ART (bar pattern). Colours show percentage of patients having more
than one plan for the offline approaches. For breast and prostate, one institution did not specify the type of ART.
Fig. 2. For the various tumour sites, fractions of users that apply ART to recover target dose and/or to improve OAR sparing. Bar patterns indicate which type of ART is
performed for site-specific graphs. Note that due to the mix of technique for different tumour sites, the bars for ‘‘any” do not have a pattern indicating technique.
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Fig. 3. (a) For the various tumour sites, fractions of users that use given imaging modalities to guide adaption (more than one response possible) (b) fractions of users that
apply given QA methods (more than on response possible). Bar patterns point at the four defined types of ART. Not that due to the mix of technique for different tumour sites,
the bars for ‘‘any” do not have a pattern indicating technique.
Fig. 4. (a) For the various tumour sites, fractions of ART users that wish to change technique or increase the rate of adaption (dark blue) or not (medium blue) as a priority.
Respondents not applying ART (non-users) but wishing to implement it to this site in priority (light blue) or not (grey). (b) Overall fractions of respondents (current users and
non-users) wishing to implement ART for any new tumour site (blue, green and yellow) or not (red). (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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the users reported using CT and/or MR imaging as well. Although
every effort was made to clearly phrase the question, it remains
unclear if CT/MR was used to take the decision to adapt (in-room
imaging or scheduled surveillance scans) or if a CT/MR was
acquired to produce the new plan once the decision to adapt had
already been taken based on other criteria. It was clear that good
image quality and high soft-tissue contrast were needed for online
daily replanning since 10 users used MR imaging and one used CT
(probably on-rail in-room CT). Three users of MR-linac for ART also
used it for RRMM (gating). One used MR-linac only for gating and
six used it for ART only, which can be explained by the fact that at
the time of the survey, only one of the two available MR-linac plat-
forms had RRMM capability.
There was a pronounced interest to change technique or
increase the use of ART for head and neck and lung cancer
(Fig. 4a). The main barriers to do so were human/material
resources and technical limitations (Fig. 5). ART for head and neck
and lung cancer was only performed offline (ad-hoc or with proto-
col) which is well suited for systematic or slow progressive
changes but puts a high demand on human resources. Lung was
also a common priority in the wishes to expand/implement RRMM
[30] which highlights the high variability in lung anatomy both on
the intra- and interfractional time-scale. These sites are clinically
challenging due to poor outcome (lung) or side effects with a high
impact on quality of life (head and neck), which indicates that the
RT community believes in the potential of higher targeting accu-
racy to improve outcome.
Two thirds of respondents wished to implement ART for a new
tumour site and 40% of these had plans to do so in the next 2 years
(Fig. 4b). While human/material resources and technical limita-
tions remained important barriers, the lack of clinical interest/rel-
evance was also highly ranked indicating the need for clinical
evidence of the potential benefit of ART. It should be acknowledged
that the wishes and barrier ranking could represent the personal
assessment of the respondent rather than the consensus opinion
of the centre.
Human/material resources were the highest ranked barriers for
both RRMM and ART [30]. Only techniques feasible with conven-
tional treatment platforms were used by more than 50% of respon-
dents (gating with breathing surrogate and offline replanning). The
overall relatively low importance given to reimbursement suggests
that RRMM and ART would be used more extensively, were they
available on standard equipment with a minimum increase in
needed resources. Documented issues for ART such as uncertain-
ties in dose accumulation [26] and target volume adaption in case
of tumour shrinkage [34,35] were not mentioned explicitely.
The percentage of ART users was larger among academic insti-
tutions with larger patient volumes (Tables A.1 and A.2), possibly
because human/material resources can potentially be (re-)
allocated more efficiently than in smaller centres. Patient selection
is important to adequately use these resources [10]. However, to
address these barriers more generally, automation for segmenta-
tion and treatment plan optimization are needed to alleviate the
planning workload [36–39]. In addition, pre-treatment phantom
measurement should be replaced with other, less resources-
intensive and more easily automated, QA methods [5,40,41].
Online daily replanning was mostly reported to be performed on
MR-linacs which are still a scarce resource requiring longer treat-
ment slots and enhanced availability of clinicians and physicists
at the unit than non-adaptive workflows, therefore putting consid-
erable stress on human/material resources [20,42]. Research in
CBCT image quality [43] and dose calculation [44,45], needed for
Fig. 5. Histogram of ranks given to the barriers to further use for an existing ART tumour site (left) or implementation for a new ART tumour site (right). A lower rank
(towards red) indicates high importance while a higher rank (towards blue) indicates lower importance. The grey bars indicate the number of institutions that considered the
barrier ‘‘not relevant”.
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online daily replanning on conventional equipment, is promising.
But ultimately, clinical use relies on the commercial availability
of such methods.
This study presents the patterns of practice at the time of data
collection in a fast-moving field. Respondents could mention their
plans for expansion at two years; nevertheless there would be an
interest in evaluating the changes in practice in the medium-
term. In particular, a platform dedicated to daily re-planning using
iteratively reconstructed CBCT [46] has been introduced shortly
after the data collection period and may change practice in the
near-future. MR-linac systems are also likely to be more wide-
spread in some years.
Centres doing ART or having an interest in the technique may
have been more likely to answer while other possible participation
bias included accessibility to the survey (on the internet and only
in English) [30]. The true proportion of users may be lower than
61% [28]. Nonetheless, with 108 users, this survey gives an inter-
esting insight in how ART is being performed currently, as well
as the wishes and barriers to expansion. In addition, with 69
non-users, the survey provides useful information on barriers to
implementation.
The participation bias may have been particularly important for
centres from middle-income countries. With only 17 respondents,
it is difficult to draw conclusions based on socio-economic status.
The availability of RT equipment and staffing was reported to be
related to socio-economic status in Europe [47,48]. The human/-
material resources needed for daily replanning or certain RRMM
techniques [30] are therefore expected to be scarcer in middle-
income countries which may explain why no centre there used
daily replanning or tracking. The percentage of ART users was nev-
ertheless as high as in high-income countries, including for plan
library and offline protocols. In a survey of Indian centres attending
a national educational activity on ART, even higher rates of offline
ART (92% for head and neck, 52% for lung and 44% for pelvis) were
reported with the lack of equipment, training and tools/manage-
ment support as main barriers [49].
Although the ESTRO-HERO study concluded that staffing levels
in Europe are equal to or higher than the ‘‘Radiation Therapy for
Cancer: Quantification of Radiation Therapy Infrastructure and
Staffing Needs” (QUARTS) recommendations, it also highlights
the variations among countries and acknowledges that human
resources needs have increased with the increased complexity of
modern RT techniques of which RRMM and ART are good examples
[50,51].
In conclusion, ART was used for a broad range of tumour sites,
mainly with ad-hoc offline replanning and for a median of 3
tumour sites per user. There was a pronounced interest in imple-
menting ART for more tumour sites, mainly limited by human/ma-
terial resources and technical limitations. More streamlined
workflows allowing for reduced treatment and QA time and staff,
as well as high-quality soft-tissue in-room imaging (especially
for daily replanning) will be key to a wider adoption of ART.
To further promote safe and effective use of both ART and
RRMM and to reduce the strain on human/material resources, we
recommend that users, future users and vendors work together
towards efficient solutions and workflows available for use on con-
ventional equipment. Further, consensus on best practice is needed
for the establishment of clear, broadly accepted guidelines. This
could also contribute to development of solid and consistent reim-
bursement practices.
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